NasdaqGS - Delayed Quote USD
Moderna, Inc. (MRNA)
27.60
-1.95
(-6.61%)
At close: August 1 at 4:00:02 PM EDT
27.73
+0.12
+(0.45%)
After hours: August 1 at 7:59:38 PM EDT
Loading Chart for MRNA
- Previous Close
29.56 - Open
27.64 - Bid 27.23 x 3000
- Ask 27.69 x 3000
- Day's Range
26.56 - 27.88 - 52 Week Range
23.15 - 91.99 - Volume
16,250,069 - Avg. Volume
10,965,124 - Market Cap (intraday)
10.676B - Beta (5Y Monthly) --
- PE Ratio (TTM)
-- - EPS (TTM)
-7.51 - Earnings Date Aug 1, 2025
- Forward Dividend & Yield --
- Ex-Dividend Date --
- 1y Target Est
45.00
Moderna, Inc., a biotechnology company, provides messenger RNA medicines in the United States, Europe, and internationally. The company's respiratory vaccines include spikevax, mRESVIA, COVID, RSV, seasonal influenza, combination, and pandemic influenza vaccine; latent vaccines comprise cytomegalovirus, epstein-barr virus, herpes simplex virus, varicella zoster virus, and human immunodeficiency virus vaccines; enteric viruses include norovirus; public health vaccines consist of Zika, Nipah, and Mpox vaccines; and bacterial diseases vaccines, such as lyme vaccines. It also provides oncology therapeutics, such as individualized neoantigen and checkpoint adaptive immune modulation therapy; and rare disease products, including propionic and methylmalonic acidemia, glycogen storage disease type 1a, ornithine transcarbamylase deficiency, phenylketonuria, crigler-najjar syndrome type 1, and cystic fibrosis. It has strategic alliances and collaborations with AstraZeneca; Merck & Co., Inc; Vertex Pharmaceuticals Incorporated; Vertex Pharmaceuticals (Europe) Limited; Generation Bio Co.; immatics N.V.; Life Edit Therapeutics; Carisma Therapeutics, Inc.; CytomX Therapeutics; Defense Advanced Research Projects Agency; Biomedical Advanced Research and Development Authority; Institute for Life Changing Medicines; The Bill & Melinda Gates Foundation; and OpenAI. The company was formerly known as Moderna Therapeutics, Inc. and changed its name to Moderna, Inc. in August 2018. Moderna, Inc. was founded in 2010 and is headquartered in Cambridge, Massachusetts.
www.modernatx.comRecent News: MRNA
View More
Performance Overview: MRNA
Trailing total returns as of 8/1/2025, which may include dividends or other distributions. Benchmark is S&P 500 (^GSPC) .
YTD Return
MRNA
33.61%
S&P 500 (^GSPC)
6.06%
1-Year Return
MRNA
70.69%
S&P 500 (^GSPC)
14.53%
3-Year Return
MRNA
82.91%
S&P 500 (^GSPC)
51.46%
5-Year Return
MRNA
62.75%
S&P 500 (^GSPC)
90.70%
Compare To: MRNA
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: MRNA
View MoreValuation Measures
As of 8/1/2025
Market Cap
10.68B
Enterprise Value
6.29B
Trailing P/E
--
Forward P/E
--
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
3.48
Price/Book (mrq)
1.14
Enterprise Value/Revenue
2.06
Enterprise Value/EBITDA
--
Financial Highlights
Profitability and Income Statement
Profit Margin
-94.31%
Return on Assets (ttm)
-14.77%
Return on Equity (ttm)
-27.50%
Revenue (ttm)
3.08B
Net Income Avi to Common (ttm)
-2.9B
Diluted EPS (ttm)
-7.51
Balance Sheet and Cash Flow
Total Cash (mrq)
5.13B
Total Debt/Equity (mrq)
7.43%
Levered Free Cash Flow (ttm)
-2.86B
Research Analysis: MRNA
View MoreResearch Reports: MRNA
View MoreModerna Earnings: Tougher Cost Cuts Show Management Commitment to 2028 Breakeven Goal
Moderna is a commercial-stage biotech that was founded in 2010 and had its initial public offering in December 2018. The firm's mRNA technology was rapidly validated with its covid vaccine, which was authorized in the United States in December 2020. Moderna had 40 mRNA development candidates in clinical development as of September 2024. Programs span a wide range of therapeutic areas, including infectious disease, oncology, cardiovascular disease, and rare genetic diseases.
RatingPrice TargetModerna: Positive Data From Phase 3 Trial of Flu Vaccine Keeps Potential 2026 Launch in Sight
Moderna is a commercial-stage biotech that was founded in 2010 and had its initial public offering in December 2018. The firm's mRNA technology was rapidly validated with its covid vaccine, which was authorized in the United States in December 2020. Moderna had 40 mRNA development candidates in clinical development as of September 2024. Programs span a wide range of therapeutic areas, including infectious disease, oncology, cardiovascular disease, and rare genetic diseases.
RatingPrice TargetModerna: Positive Data From Phase 3 Trial of Flu Vaccine Keeps Potential 2026 Launch in Sight
Moderna is a commercial-stage biotech that was founded in 2010 and had its initial public offering in December 2018. The firm's mRNA technology was rapidly validated with its covid vaccine, which was authorized in the United States in December 2020. Moderna had 40 mRNA development candidates in clinical development as of September 2024. Programs span a wide range of therapeutic areas, including infectious disease, oncology, cardiovascular disease, and rare genetic diseases.
RatingPrice TargetMid Cap U.S. Pick List June 2025
This pick list highlights constituents of the Morningstar US Mid Cap Index that we believe offer investors the best risk-adjusted return prospects. The market capitalization range for U.S. mid-caps typically falls between $1 billion and $8 billion and represents 20% of the total capitalization of the U.S. equity market.
Top Analysts: MRNA
View MoreOverall Score
Discover which analysts rank highest for MRNA overall weighted by direction, price target, and price movement.
Learn MoreGoldman Sachs 67/100
Direction Score
Discover which analysts rank highest on predicting the directional movement of MRNA.
Learn MoreArgus Research 47/100
Price Score
Discover which analysts rank highest on predicting the price target of MRNA.
Learn MoreHSBC 99/100